Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in HER2+ Pretreated NSCLC
NCT00758134Phase 2Terminated
- Sponsor
- Armando Santoro
- Start
- Jul 2008
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in non-small cell lung cancer (NSCLC), sponsored by Armando Santoro. Started Jul 2008; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00758134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758134.